4-氯噻唑-5-羧酸乙酯 | 444909-55-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-氯噻唑-5-羧酸乙酯
• 中文别名: 4-氯噻唑-5-甲酸乙酯
• 英文名称: ethyl 4-chlorothiazole-5-carboxylate
• 英文别名: ethyl 4-chloro-1,3-thiazole-5-carboxylate
• CAS: 444909-55-1
• 化学式: C₆H₆ClNO₂S
• mdl: MFCD10478282
• 分子量: 191.638
• InChiKey: SVKUSYRTZMFDEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  三氟甲磺酰胺 、 4-氯噻唑-5-羧酸乙酯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以34%的产率得到ethyl 4-(trifluoromethylsulfonylamino)thiazole-5-carboxylate
  参考文献：
  名称：

  [EN] SULFONAMIDE-HETEROCYCLIC HERBICIDAL COMPOUNDS
  [FR] COMPOSÉS HERBICIDES HÉTÉROCYCLIQUES DE SULFONAMIDE

  摘要：

  本发明涉及式(I)的磺胺苯酰胺衍生物，其中A、W、X、Z、m、n、p、R、R1、R2、R5、R6、R11和R12如规范中定义。此外，本发明涉及包含这些化合物的除草剂组合物，以及使用这些化合物控制植物生长的方法。

  公开号：

  WO2015004282A1

文献信息

• [EN] HISTONE METHYLTRANSFERASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE MÉTHYLTRANSFÉRASE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2018119208A1

  公开（公告）日：2018-06-28

  The present disclosure provides certain angular tricyclic compounds that are histone methyltransi erases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta- thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了一些角三环化合物，这些化合物是组蛋白甲基转移酶G9a和/或GLP的抑制剂，因此可用于治疗可以通过抑制G9a和/或GLP来治疗的疾病，例如癌症和血红蛋白病（例如，β-地中海贫血和镰状细胞病）。还提供了含有这些化合物的药物组合物以及制备这些化合物的方法。
• Pyrrolyl-and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
  申请人：Marfat Anthony

  公开号：US06869945B2

  公开（公告）日：2005-03-22

  This application is directed to compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: where Y is ═C(R 1 a )— or —[N→(O) k ]— where k is 0 or 1; G 1 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic, or that is a 7- to 12-membered, fused polycyclic; provided that G 1 is not a discontinuous or restricted biaryl moiety as defined under G 2 ; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; -G 2 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic; or that is a 7- to 12-membered, fused polycyclic; or that is a 7- to 18-membered discontinuous or restricted biaryl moiety; wherein for each of the carbon ring systems recited, optionally one carbon atom of said carbon ring system may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; E is selected from: and all other substituents shown above are as defined in the specification.

  本申请涉及一种化合物，其可用作PDE4的抑制剂，用于治疗由嗜酸性粒细胞的激活和脱颗粒调节的疾病，特别是哮喘、慢性支气管炎和慢性阻塞性肺疾病，其化学式为：其中Y为═C（R1a）—或—[N→（O）k]—，其中k为0或1；G1为饱和或不饱和的碳环系统，是一个3-至7-成员的单环，或是一个7-至12-成员的融合多环；前提是G1不是根据G2下定义的不连续或受限制的双芳基基团；其中可选地，一个碳原子可被N、O和S中选择的一个杂原子所替换；其中可选地，其第二个碳原子，进一步可选地，其第三个碳原子可被N所替换；-G2为饱和或不饱和的碳环系统，是一个3-至7-成员的单环；或是一个7-至12-成员的融合多环；或是一个7-至18-成员的不连续或受限制的双芳基基团；其中对于所述的每个碳环系统，可选地，其一个碳原子可被N、O和S中选择的一个杂原子所替换；其中可选地，其第二个碳原子，进一步可选地，其第三个碳原子可被N所替换；E选择自：以及上述所有其他取代基在规范中定义。
• Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
  申请人：Marfat Anthony

  公开号：US06894041B2

  公开（公告）日：2005-05-17

  This application is directed to compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: where Y is ═C(R 1 a )— or —[N (O) k ]— where k is 0 or 1; G 1 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic, or that is a 7- to 12-membered, fused polycyclic; provided that G 1 is not a discontinuous or restricted biaryl moiety as defined under G 2 ; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; —G 2 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic; or that is a 7- to 12-membered, fused polycyclic; or that is a 7- to 18-membered discontinuous or restricted biaryl moiety; wherein for each of the carbon ring systems recited, optionally one carbon atom of said carbon ring system may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; and E is selected from: and all other substituents shown above are as defined in the specification.

  本申请涉及的化合物可用作PDE4的抑制剂，用于治疗由嗜酸性粒细胞的激活和脱颗粒调节的疾病，特别是哮喘、慢性支气管炎和慢性阻塞性肺疾病，其化学式为：其中Y为═C（R1a）-或-[N（O）k]-，其中k为0或1；G1为饱和或不饱和的碳环系统，是3-至7-成员的单环，或是7-至12-成员的融合多环；但要求G1不是根据G2定义的不连续或受限的双芳基基团；其中可选地，一个碳原子可以被来自N、O和S的杂原子所取代；其中可选地，第二个碳原子和进一步可选地第三个碳原子可以被N所取代；-G2为饱和或不饱和的碳环系统，是3-至7-成员的单环，或是7-至12-成员的融合多环；或是7-至18-成员的不连续或受限的双芳基基团；对于所述的每个碳环系统，可选地，其中一个碳原子可以被N、O和S中选择的杂原子所取代；其中可选地，第二个碳原子和进一步可选地第三个碳原子可以被N所取代；E选自：以及上述所有其他取代基在说明书中定义。
• Thiazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
  申请人：Pfizer Inc

  公开号：US06559168B2

  公开（公告）日：2003-05-06

  This application is directed to compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: where Y is ═C(R1a)— or —[N□(O)k]— where k is 0 or 1; G1 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic, or that is a 7- to 12-membered, fused polycyclic; provided that G1 is not a discontinuous or restricted biaryl moiety as defined under G2; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; —G2 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic; or that is a 7- to 12-membered, fused polycyclic; or that is a 7- to 18-membered discontinuous or restricted biaryl moiety; wherein for each of the carbon ring systems recited, optionally one carbon atom of said carbon ring system may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; E is selected from: and all other substituents shown above are as defined in the specification.

  本申请涉及的化合物可用作PDE4抑制剂，用于治疗由嗜酸性粒细胞的激活和脱颗粒调节的疾病，特别是哮喘，慢性支气管炎和慢性阻塞性肺疾病，其化学式为：其中Y为═C（R1a）—或—[N□(O)k]—，其中k为0或1；G1是饱和或不饱和的碳环系统，是3-至7-成员的单环，或是7-至12-成员的融合多环；但要求G1不是根据G2定义的不连续或受限的双芳基基团；其中可以用N，O和S中选择的杂原子替换其中一个碳原子；其中第二个碳原子和进一步选择的第三个碳原子可以用N替换；—G2是饱和或不饱和的碳环系统，是3-至7-成员的单环；或是7-至12-成员的融合多环；或是7-至18-成员的不连续或受限的双芳基基团；其中对于所述的每个碳环系统，可以选择用N，O和S中的杂原子替换其中一个碳原子；其中第二个碳原子和进一步选择的第三个碳原子可以用N替换；E选择自：所有上述其他取代基如说明书所定义。
• Histone methyltransferase inhibitors
  申请人：GLOBAL BLOOD THERAPEUTICS, INC.

  公开号：US10829452B2

  公开（公告）日：2020-11-10

  The present disclosure provides compounds of Formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. where R1, alk, R2, Z1, Z2, X, R3, R4, B, a, and b are as described herein.

  本公开提供的式(I)化合物是组蛋白甲基转移酶G9a和/或GLP抑制剂，因此可用于治疗可通过抑制G9a和/或GLP治疗的疾病，如癌症和血红蛋白病（如β地中海贫血和镰状细胞病）。此外，还提供了含有此类化合物的药物组合物和制备此类化合物的工艺。 其中 R1、alk、R2、Z1、Z2、X、R3、R4、B、a 和 b 如本文所述。